RESEARCH PROFILE
TIRZEPATIDE
Dual GIP & GLP 1 Receptor Agonist
Tirzepatide is a long acting peptide that activates two metabolic hormone receptors within a single molecule: glucose dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 (GLP 1). It has extensive human clinical evidence across type 2 diabetes, obesity, and obesity related conditions.
FDA APPROVED ACTIVE INGREDIENT • DUAL GIP & GLP 1 AGONIST • EXTENSIVE HUMAN CLINICAL EVIDENCE
TIRZEPATIDE AT A GLANCE
Category
Dual hormone receptor agonist
Alternate / Development Name
LY3298176
Primary Targets
GIP • GLP 1
Drug Class
Incretin based therapy
Regulatory Status
FDA approved in specific formulations and indications
Human Evidence
Extensive Phase 3 and clinical outcomes research
Tirzepatide was first FDA approved in 2022 as Mounjaro for improving glycemic control in adults with type 2 diabetes. Zepbound was subsequently approved in 2023 for chronic weight management in qualifying adults and in 2024 for moderate to severe obstructive sleep apnea in adults with obesity. U.S. Food and Drug Administration
Important distinction: FDA approval applies to specific tirzepatide drug products, formulations, indications, strengths, and manufacturing systems. It does not establish FDA approval of unrelated research products containing or represented as tirzepatide.
WHAT IS TIRZEPATIDE?
Tirzepatide is a synthetic, long acting peptide engineered to activate both the GIP receptor and GLP 1 receptor.
It is a 39 amino acid peptide based partly on the GIP sequence and incorporates structural modifications that extend its duration of activity. FDA documentation describes a fatty diacid component that contributes to prolonged exposure and supports once weekly administration in approved formulations. FDA Access Data
GIP and GLP 1 are naturally occurring incretin hormones involved in the physiological response to nutrient intake.
Both participate in glucose dependent insulin signaling and metabolic regulation, while GLP 1 signaling also has established effects on appetite, food intake, glucagon secretion, and gastric function.
Tirzepatide combines activity at both receptor systems within a single molecule.
MECHANISM OF ACTION
Tirzepatide simultaneously activates two incretin receptor systems.
GIP RECEPTOR
GIP, or glucose dependent insulinotropic polypeptide, is an incretin hormone released in response to nutrient intake.
GIP receptor activation contributes to glucose dependent insulin secretion and participates in nutrient and metabolic signaling.
GLP 1 RECEPTOR
GLP 1 receptor activation influences several metabolic processes, including:
Appetite and satiety
Food intake
Glucose dependent insulin secretion
Glucagon regulation
Gastric function
DUAL RECEPTOR SIGNALING
The defining characteristic of tirzepatide is that GIP and GLP 1 receptor activity occur within the same molecule.
This differentiates tirzepatide from medications such as semaglutide, which primarily target the GLP 1 receptor.
The combined signaling affects glucose regulation, appetite and food intake, and body weight, forming the mechanistic basis for tirzepatide's clinical development in diabetes and obesity.
WHAT THE RESEARCH SHOWS
TYPE 2 DIABETES EVIDENCE
The SURPASS clinical trial program established an extensive human evidence base for tirzepatide in type 2 diabetes.
Trials demonstrated substantial reductions in glycated hemoglobin, or HbA1c, together with reductions in body weight.
In the SURPASS 2 trial, tirzepatide was directly compared with once weekly semaglutide in adults with type 2 diabetes. The study contributed to the evidence supporting tirzepatide as a dual GIP and GLP 1 receptor agonist for glycemic management. New England Journal of Medicine
OBESITY EVIDENCE
The pivotal SURMOUNT 1 trial studied 2,539 adults with obesity or overweight plus at least one weight related complication, excluding diabetes.
Participants received tirzepatide or placebo for 72 weeks.
Mean body weight changes at week 72 were:
5 mg: −15.0%
10 mg: −19.5%
15 mg: −20.9%
Placebo: −3.1%
The most common adverse events were gastrointestinal and were predominantly mild to moderate, occurring mainly during dose escalation. New England Journal of Medicine
LONG TERM OBESITY & PREDIABETES RESEARCH
An extended analysis of SURMOUNT 1 followed participants with obesity and prediabetes for 176 weeks.
At 176 weeks, mean body weight changes were:
5 mg: −12.3%
10 mg: −18.7%
15 mg: −19.7%
Placebo: −1.3%
During the treatment period, type 2 diabetes was diagnosed in 1.3% of participants receiving tirzepatide compared with 13.3% receiving placebo.
These findings provide longer term evidence regarding weight reduction and progression from prediabetes to type 2 diabetes in the studied population. New England Journal of Medicine
OBSTRUCTIVE SLEEP APNEA
Tirzepatide has also been studied in adults with obesity and moderate to severe obstructive sleep apnea.
Two randomized, double blind, placebo controlled Phase 3 trials evaluated tirzepatide over 52 weeks.
The studies demonstrated improvements in the apnea hypopnea index and formed the basis for FDA approval of Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. U.S. Food and Drug Administration
CARDIOVASCULAR OUTCOMES
The SURPASS CVOT cardiovascular outcomes trial enrolled more than 13,000 people with type 2 diabetes and established atherosclerotic cardiovascular disease.
Tirzepatide was compared with dulaglutide.
Major adverse cardiovascular events occurred in 12.2% of participants assigned tirzepatide and 13.1% assigned dulaglutide.
The trial established noninferiority of tirzepatide to dulaglutide for the primary cardiovascular endpoint; superiority was not statistically established for that endpoint. New England Journal of Medicine
IMPORTANT EVIDENCE LIMITATIONS
Tirzepatide has substantial human evidence, but clinical findings must still be interpreted according to the specific population, formulation, dose, indication, and study design.
Results obtained with FDA approved Mounjaro or Zepbound cannot automatically be attributed to compounded, research grade, or otherwise unapproved tirzepatide products.
Clinical trial averages also do not predict an individual person's response.
SAFETY & RESEARCH CONSIDERATIONS
Tirzepatide has been evaluated in large clinical development programs and has established FDA prescribing information.
Its safety profile nevertheless includes important adverse effects, warnings, contraindications, and monitoring considerations.
COMMONLY REPORTED
Gastrointestinal adverse effects are among the most frequently reported.
These can include:
Nausea
Diarrhea
Vomiting
Constipation
Abdominal discomfort or pain
Dyspepsia
In obesity trials, gastrointestinal events occurred most frequently during dose escalation and were generally mild to moderate. New England Journal of Medicine
GALLBLADDER & PANCREATIC CONSIDERATIONS
Acute gallbladder disease has been reported in clinical studies of tirzepatide.
Acute pancreatitis has also been reported with incretin based therapies. Severe or persistent abdominal symptoms require appropriate medical evaluation.
HYPOGLYCEMIA
Tirzepatide stimulates insulin secretion in a glucose dependent manner.
The risk of hypoglycemia can nevertheless increase when tirzepatide is used with medications such as insulin or insulin secretagogues.
GASTRIC EMPTYING
Tirzepatide delays gastric emptying.
This can contribute to gastrointestinal effects and may affect absorption of some orally administered medications.
THYROID C CELL TUMOR WARNING
FDA approved tirzepatide products carry a boxed warning concerning thyroid C cell tumors.
Tirzepatide caused thyroid C cell tumors in rats. It is unknown whether tirzepatide causes thyroid C cell tumors, including medullary thyroid carcinoma, in humans.
FDA labeling contraindicates its use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
REGULATORY CONTEXT
TIRZEPATIDE IS AN FDA APPROVED ACTIVE INGREDIENT
This is an important distinction from investigational compounds such as Retatrutide.
Tirzepatide is the active ingredient in FDA approved prescription drug products.
MOUNJARO
Mounjaro was FDA approved in 2022 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. FDA Access Data
ZEPBOUND
Zepbound was FDA approved in 2023 for chronic weight management in qualifying adults with obesity or overweight plus at least one weight related condition, together with reduced calorie intake and increased physical activity. U.S. Food and Drug Administration
OBSTRUCTIVE SLEEP APNEA
In December 2024, FDA approved Zepbound for treatment of moderate to severe obstructive sleep apnea in adults with obesity, together with reduced calorie intake and increased physical activity.
It was the first FDA approved medication specifically for certain patients with obstructive sleep apnea. U.S. Food and Drug Administration
FDA APPROVAL DOES NOT TRANSFER BETWEEN PRODUCTS
The regulatory status of the tirzepatide molecule must be distinguished from the regulatory status of a particular product.
FDA approval applies to specific formulations, manufacturing controls, strengths, routes of administration, labeling, and indications.
A research grade or otherwise unapproved product represented as containing tirzepatide should therefore not be described as FDA approved simply because Mounjaro and Zepbound are approved drugs.
Regulatory context matters. Clinical evidence from FDA approved tirzepatide products does not independently establish the safety, effectiveness, quality, or regulatory status of an unrelated research product.
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation for specific samples and lots represented in its research library.
TIRZEPATIDE 60 MG
Laboratory
Optiq Health Labs
Lot
kizen72826
Sample ID
1276.OPT.260910
Report Date
September 18, 2026
Sample Matrix
Lyophilized Peptide
Intended Use
Research Use Only Tirzepatide 60mg COA
Reported Net Content
58.97 mg/vial
Reported Purity
99.5%
Identity
LC MS confirmation • Tirzepatide tested
Endotoxin
Pass • LAL ≤ 0.05 EU/mg
Sterility
Pass • USP <71> • No Growth Tirzepatide 60mg COA
IMPORTANT COA LIMITATION
Analytical results apply only to the specific sample identified in the corresponding laboratory report.
The laboratory states that its findings are limited to the sample received and tested and do not represent or warrant the quality, composition, or characteristics of any other sample, lot, batch, product, or material. The laboratory also does not make claims regarding clinical efficacy, safety, suitability, or intended use. Tirzepatide 60mg COA
A passing analytical result should therefore not be interpreted as establishing FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated Tirzepatide samples or lots.
SELECTED RESEARCH & REFERENCES
Jastreboff AM, et al.
Tirzepatide Once Weekly for the Treatment of Obesity.
New England Journal of Medicine. 2022;387:205–216.
DOI: 10.1056/NEJMoa2206038 New England Journal of Medicine
Jastreboff AM, et al.
Tirzepatide for Obesity Treatment and Diabetes Prevention.
New England Journal of Medicine. 2025;392:958–971.
Long term SURMOUNT 1 analysis. New England Journal of Medicine
Frías JP, et al.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
New England Journal of Medicine. 2021;385:503–515.
SURPASS 2. New England Journal of Medicine
Nicholls SJ, et al.
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
New England Journal of Medicine.
SURPASS CVOT. New England Journal of Medicine
U.S. Food & Drug Administration
Zepbound approval for chronic weight management. U.S. Food and Drug Administration
U.S. Food & Drug Administration
Zepbound approval for moderate to severe obstructive sleep apnea in adults with obesity. U.S. Food and Drug Administration
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice.
Tirzepatide is an FDA approved active pharmaceutical ingredient used in specific approved prescription drug products and indications. FDA approval of those products should not be interpreted as FDA approval of unrelated research grade, compounded, or other unapproved tirzepatide products.
Evidence and regulatory status can differ by formulation, route of administration, dose, population, and intended use.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.